Amplia Therapeutics Ltd has released a press release.
Corporate Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- App 4C - Quarterly Statement of Cashflows - June 2017 Qtr
- No Change in Trial Outcome Following Additional Analysis
- Top-Line Results for Trial of MIS416
- FDA Clearance - MIS416 Investigational New Drug Application
- Preliminary Final Report - Year Ended 31 March 2017
Later from Amplia Therapeutics
- Appendix 4C - September 2017 Quarter Cashflows
- Half Yearly Report and Accounts - HY ending 30 Sep 2017
- Appendix 4C - December 2017 Quarter
- S&P DJ Indices Announces March Quarterly Rebalance
- Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics